More than 3.6 million baits containing a recombinant vaccinia virus–rabies glycoprotein (V-RG) oral rabies vaccine were aerially or hand-distributed during 1999–2006 in an approximate 4,000-9,000 km2 area of eastern Ontario, Canada, as part of a multitactic approach to control the raccoon variant of rabies. The efficacy of the program was assessed through the collection and testing of >6,900 animals for bait acceptance and rabies virus-specific antibodies. Raccoon acceptance of rabies vaccine baits was significantly greater (71–83%) in areas baited at a density of 150 baits/km2 compared to areas baited at 75 baits/km2 (26–58%), and more raccoons consumed vaccine baits in areas baited with a flight line spacing of 0.75 km (45.3%[321/708[) than with a spacing of 1.5 km (33.8% [108/320[). In addition, greater numbers of raccoons consumed vaccine baits during a drop in September (52.7%[213/404[) as opposed to a June bait drop (34.6% [216/624[). Seropositivity rates for raccoons ranged between 7% and 28% in areas baited at 75/km2 and 10% to 27% in areas baited at 150/km2 with statistical differences varying among years and treatments. The last case of raccoon-variant rabies reported in Ontario was in September 2005. The control of raccoon rabies in Ontario has resulted in an estimated $6M to $10M Cdn annual savings in rabies-associated costs.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 44 • No. 4